MY202967A - Semaglutide in cardiovascular conditions - Google Patents

Semaglutide in cardiovascular conditions

Info

Publication number
MY202967A
MY202967A MYPI2018703725A MYPI2018703725A MY202967A MY 202967 A MY202967 A MY 202967A MY PI2018703725 A MYPI2018703725 A MY PI2018703725A MY PI2018703725 A MYPI2018703725 A MY PI2018703725A MY 202967 A MY202967 A MY 202967A
Authority
MY
Malaysia
Prior art keywords
semaglutide
cardiovascular conditions
cardiovascular
conditions
glp
Prior art date
Application number
MYPI2018703725A
Other languages
English (en)
Inventor
Oluf Kristian Hjbjerg Hansen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58668875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY202967(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MY202967A publication Critical patent/MY202967A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
MYPI2018703725A 2016-04-28 2017-04-28 Semaglutide in cardiovascular conditions MY202967A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16167458 2016-04-28
EP16188262 2016-09-12
PCT/EP2017/060160 WO2017186896A1 (en) 2016-04-28 2017-04-28 Semaglutide in cardiovascular conditions

Publications (1)

Publication Number Publication Date
MY202967A true MY202967A (en) 2024-05-31

Family

ID=58668875

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2018703725A MY202967A (en) 2016-04-28 2017-04-28 Semaglutide in cardiovascular conditions

Country Status (24)

Country Link
US (3) US20190134162A1 (cg-RX-API-DMAC7.html)
EP (1) EP3448416B1 (cg-RX-API-DMAC7.html)
JP (1) JP7221694B2 (cg-RX-API-DMAC7.html)
KR (3) KR20250038818A (cg-RX-API-DMAC7.html)
CN (1) CN109069589B (cg-RX-API-DMAC7.html)
AU (2) AU2017256774B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018072020A2 (cg-RX-API-DMAC7.html)
CA (1) CA3022535A1 (cg-RX-API-DMAC7.html)
CL (1) CL2018003045A1 (cg-RX-API-DMAC7.html)
DK (1) DK3448416T3 (cg-RX-API-DMAC7.html)
ES (1) ES2928007T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20221150T1 (cg-RX-API-DMAC7.html)
HU (1) HUE060040T2 (cg-RX-API-DMAC7.html)
IL (1) IL262390B1 (cg-RX-API-DMAC7.html)
MA (1) MA44762A (cg-RX-API-DMAC7.html)
MX (1) MX2018012700A (cg-RX-API-DMAC7.html)
MY (1) MY202967A (cg-RX-API-DMAC7.html)
PH (1) PH12018502274B1 (cg-RX-API-DMAC7.html)
PL (1) PL3448416T3 (cg-RX-API-DMAC7.html)
RS (1) RS63630B1 (cg-RX-API-DMAC7.html)
RU (1) RU2768283C2 (cg-RX-API-DMAC7.html)
SI (1) SI3448416T1 (cg-RX-API-DMAC7.html)
WO (1) WO2017186896A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA202507395B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2768283C2 (ru) * 2016-04-28 2022-03-23 Ново Нордиск А/С Семаглутид при сердечно-сосудистых состояниях
TWI847306B (zh) 2017-08-24 2024-07-01 丹麥商諾佛 儂迪克股份有限公司 Ｇｌｐ-１組成物及其用途
HRP20230929T1 (hr) * 2018-10-26 2023-11-24 Novo Nordisk A/S Stabilni pripravci semaglutida i njihova upotreba
ES2994462T3 (en) * 2018-12-21 2025-01-24 Novo Nordisk As Process of spray drying of glp-1 peptide
PE20230819A1 (es) * 2020-02-18 2023-05-19 Novo Nordisk As Composiciones y usos de glp-1
CN114699510B (zh) * 2021-12-29 2024-07-16 浙江湃肽生物有限公司 一种司美格鲁肽微针阵列及其制备方法
AU2023285400A1 (en) * 2022-06-08 2024-12-05 Zydus Lifesciences Limited Reusable multi-dose, variable dose, single pen injector for type 2 diabetes and weight management
CN117462654A (zh) * 2023-09-28 2024-01-30 武汉大学人民医院（湖北省人民医院） 司美格鲁肽在制备预防或治疗心肌重构的药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003084563A1 (en) * 2002-04-04 2003-10-16 Novo Nordisk A/S Glp-1 agonist and cardiovascular complications
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
CN107961377B (zh) * 2010-05-05 2022-11-22 勃林格殷格翰国际有限公司 组合疗法
PT2651398T (pt) * 2010-12-16 2018-03-09 Novo Nordisk As Composições sólidas compreendendo um agonista de glp-1 e um sal de ácido n-(8-(2-hidroxibenzoil)amino) caprílico
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
JP6126097B2 (ja) * 2011-09-06 2017-05-10 ノヴォ ノルディスク アー／エス Ｇｌｐ−１誘導体
WO2015071355A1 (en) * 2013-11-15 2015-05-21 Novo Nordisk A/S Selective pyy compounds and uses thereof
RU2768283C2 (ru) 2016-04-28 2022-03-23 Ново Нордиск А/С Семаглутид при сердечно-сосудистых состояниях

Also Published As

Publication number Publication date
BR112018072020A2 (pt) 2019-02-12
AU2017256774B2 (en) 2024-07-11
RU2018140900A (ru) 2020-05-28
MA44762A (fr) 2019-03-06
KR102778218B1 (ko) 2025-03-10
JP2019514925A (ja) 2019-06-06
EP3448416A1 (en) 2019-03-06
AU2017256774A1 (en) 2018-11-01
RS63630B1 (sr) 2022-10-31
PH12018502274B1 (en) 2024-02-28
WO2017186896A1 (en) 2017-11-02
MX2018012700A (es) 2019-01-30
KR20180135012A (ko) 2018-12-19
PH12018502274A1 (en) 2019-09-09
CA3022535A1 (en) 2017-11-02
US20250262281A1 (en) 2025-08-21
KR20250038818A (ko) 2025-03-19
RU2768283C2 (ru) 2022-03-23
HUE060040T2 (hu) 2023-01-28
SI3448416T1 (sl) 2022-10-28
CN109069589A (zh) 2018-12-21
US20190134162A1 (en) 2019-05-09
IL262390B1 (en) 2023-05-01
ZA202507395B (en) 2025-09-25
KR20220147712A (ko) 2022-11-03
CN109069589B (zh) 2022-09-06
JP7221694B2 (ja) 2023-02-14
RU2018140900A3 (cg-RX-API-DMAC7.html) 2020-09-28
PL3448416T3 (pl) 2022-11-07
ES2928007T3 (es) 2022-11-14
ZA202507394B (en) 2025-09-25
IL262390A (en) 2018-12-31
HRP20221150T1 (hr) 2022-11-25
US20250288649A1 (en) 2025-09-18
CL2018003045A1 (es) 2018-12-14
DK3448416T3 (da) 2022-10-03
EP3448416B1 (en) 2022-08-10
AU2024227113A1 (en) 2024-10-31

Similar Documents

Publication Publication Date Title
ZA202507394B (en) Semaglutide in cardiovascular conditions
ZA201904616B (en) Glp-1 receptor agonists and uses thereof
MX2020014121A (es) Agonistas parciales del receptor de insulina.
MX2018005132A (es) Agonistas del receptor de glucagon.
PH12016501700A1 (en) Combination therapies with anti-cd38 antibodies
IL251027A0 (en) History of pyrrolopyrimidines as nr2b nmda receptor antagonists
WO2017100107A3 (en) Co-agonists of the glucagon and glp-1 receptors
MX2016015631A (es) Nuevos compuestos.
PH12018501844B1 (en) Liraglutide in cardiovascular conditions
PH12016500044B1 (en) Vasopressin-2 receptor agonists
GB201513543D0 (en) Compositions for use in the treatment of diabetes
UA92304U (ru) Применение ралейкина (антагониста рецепторов интерлейкина-1) как средства противодиабетического действия для терапии инсулиннезависимого сахарного диабета
PH12014000104A1 (en) Therapeutic methods and compositions for treating diabetes
IN2014CH01195A (cg-RX-API-DMAC7.html)
UA88242U (ru) Применение ралейкина (антагониста рецепторов интерлейкина-1) как средства гипогликемического действия